US EditionVIVES Partners contributes to €84m funding for radiopharma company, Nuclidium - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium - Pharmafile
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing for Swiss radiopharma company, Nuclidium. The company will use the funds to advance the development of its Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline, applicable to multiple oncology indications. The funding round was led by Kurma Growth Opportunities […] The post VIVES Partners contributes to €84m funding for radiop…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
